Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

MICHAEL E STEUER MD PC

NPI: 1114276052 · JACKSON, TN 38305 · Durable Medical Equipment & Medical Supplies · NPI assigned 09/06/2012

$1.02M
Total Medicaid Paid
67,028
Total Claims
54,859
Beneficiaries
25
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialSTEUER, MICHAEL (OWNER/PRESIDENT)
NPI Enumeration Date09/06/2012

Related Entities

Other providers sharing the same authorized official: STEUER, MICHAEL

ProviderCityStateTotal Paid
MICHAEL E STEUER, MD, PC CORDOVA TN $2.63M
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC GERMANTOWN TN $2.08M
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC SOUTHAVEN MS $742K
MICHAEL E STEUER MD PC SOUTHAVEN MS $637K
MICHAEL E STEUER MD PC TUPELO MS $266K
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC JACKSON TN $252K
MICHAEL E. STEUER MD PC OXFORD MS $234K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 5,732 $75K
2019 11,233 $192K
2020 9,801 $147K
2021 10,628 $164K
2022 9,891 $158K
2023 10,040 $150K
2024 9,703 $133K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 18,356 15,101 $383K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 14,464 12,587 $251K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 14,360 11,352 $97K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 1,510 1,248 $70K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 1,587 1,320 $50K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 7,242 5,826 $49K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 2,747 2,192 $43K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 2,617 2,219 $34K
L0650 Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf 52 26 $9K
64493 626 396 $7K
64483 193 141 $7K
64635 84 61 $5K
64494 624 395 $4K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 206 198 $2K
64636 84 61 $2K
64484 129 93 $2K
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) 992 715 $2K
99152 166 145 $693.35
64495 190 103 $629.75
81025 154 126 $399.59
80305 543 478 $313.08
27096 18 13 $303.73
77002 51 39 $164.23
20610 17 12 $159.47
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 16 12 $52.62